by Valeo Pharma | Nov 3, 2021 | Communiqué de presse
• Première inscription publique provinciale obtenue pour ces deux médicaments pour l’asthme • Couverture supplémentaire de remboursement public provincial à venir sous peu • 85% de couverture des régimes de santé privés à travers le...
by Valeo Pharma | Oct 13, 2021 | Communiqué de presse
• Les deux ententes d’inscription des organismes de regroupement d’achats couvrent RedescaMC et Redesca HPMC ainsi que 3 autres produits hospitaliers • Les deux ententes d’inscription de produits sont en vigueur depuis le 1er octobre 2021 • Les...
by Valeo Pharma | Sep 22, 2021 | News Release
Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter. Record gross margin of $2.2 million, up 1602% over Q3 2020 and 204% over prior quarter. Record 9 months revenues at $10.2 million, up 94%. Private and public reimbursement...
by Valeo Pharma | Jun 29, 2021 | News Release
Q2-21 record revenues of $2.65 million, up 27% vs Q2-20 and up 42% over prior quarter Q3-21 revenues expected to increase by more than 50% over Q2-21 Redesca launched in late Q2-21 Enerzair® Breezhaler® and Atectura® Breezhaler® commercial shipments commenced...
by Valeo Pharma | Jun 29, 2021 | News Release
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES MONTREAL, QC – June 29, 2021 – Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, is pleased to announce the closing...
